| Prostate adenocarcinoma, NOS | 20% CK7+, 15% CK20+, >95% CD57+, >90% PSA, <90% Prostein, <80% PSMA, 50% ERG+, <5% mCEA |
| Renal cell carcinoma, NOS | 30% CK7+, <5% CK20+, >90% PAX8, 60% RCC, 80% CD10, 50% Napsin A, <10% mCEA |
| Hepatocellular carcinoma, NOS | <20% CK7+, <10% CK20+, >90% Arginase 1+, >70% Glypican 3+, 30% EPCAM+, >80% CK8/18+, <20% CK7+, 10% CK19+, 20% mCEA+, 70% pCEA (canalicular pattern) |
| Neuroendocrine carcinoma, NOS | 50% CK7+, <5% CK20+, 70% Synaptophysin+, 60% Chromogranin+, 90%EpCAM+, 75% PAX5+, 50% TTF1+, 40% mCEA |
| Squamous cell carcinoma, NOS | <40% CK7+ (depending on location/origin), <1% CK20+, >95% P63+, >90% P40, >95% CK5+, 90% CK5/6+, >90% CD141+, 90%CK14+, 85% CK17+, 65% EpCAM+ (endodermal origin), 65% CK19+, 50% mCEA+/- (endodermal origin), 50% Podoplanin+, >30% CK7+, 25% Calretinin+, <10%+CD56+, <10% CA125+, 15% – 80% GATA3–/+ (depending on origin) |
| Adrenal cortical carcinoma, NOS | <5% CK7+, <1% CK20+, <90% SF1, <90% Melan A (clone A103), <90% Inhibin, 0% mCEA+ |
| |